Saturday, 31 October 2026European Markets

INPOST Stock 13.23% Up Before The Weekend

Loading stream...

(VIANEWS) - The Market ended the session with INPOST (INPST.AS) rising 13.23% to €18.14 on Friday, after five successive sessions in a row of losses. AEX-Index fell 1.41% to €879.29, after three sequential sessions in a row of losses, on what was an all-around bearish trend exchanging session today.

INPOST's last close was €16.02, 8.87% under its 52-week high of €17.58.

About INPOST

InPost S.A., together with its subsidiaries, operates as an out-of-home e-commerce enablement platform providing parcel locker services in Europe. It operates through four segments: APM (Automated Parcel Machines), To-Door, Mondial Relay, and International Other. The APM segment focuses on the delivery of parcels to APM. The To-Door segment delivers parcels using door-to-door couriers. The Mondial Relay segment delivers parcels to APM; and operates pick-up drop-off (PUDO) points in France, Spain, Belgium, the Netherlands, Luxembourg, and Portugal. The International Other segment delivers parcels to APM and PUDO points in the United Kingdom and Italy. The company also provides fulfilment services; marketing and IT services; InPost Pay services; and platform for fast-moving consumer goods products through InPost Fresh app. InPost S.A. was founded in 1999 and is headquartered in Luxembourg, Luxembourg.

Earnings Per Share

As for profitability, INPOST has a trailing twelve months EPS of €0.37.

PE Ratio

INPOST has a trailing twelve months price to earnings ratio of 49.03. Meaning, the purchaser of the share is investing €49.03 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 72.91%.

More news about INPOST (INPST.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com